Rhythm Pharmaceuticals has commercially launched IMCIVREE (setmelanotide) in Japan for treating acquired hypothalamic obesity (HO), following approval by Japan's Ministry of Health and inclusion on the National Health Insurance drug price list. IMCIVREE is the first approved therapy in Japan for this rare condition, affecting an estimated 5,000 to 8,000 people. The approval was supported by positive Phase 3 trial results showing significant BMI reduction. This launch marks a major step in providing new treatment options for patients with rare neuroendocrine diseases in Japan and globally.
Rhythm Pharmaceuticals' launch of IMCIVREE in Japan for acquired hypothalamic obesity provides context for health-sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 06:21 WIB: of 128 priced US health-sector stocks, 29 rose and 99 fell. Notable movers include CTXR at USD 0.47 with a -5.60% change and 100% buy orders, JNJ at USD 249.35 with a -5.45% change and 57% buy orders, and HRTX at USD 0.39 with a -5.32% change and 39% buy orders.
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
On October 13, 2026, several stocks including Adlai Nortye, Omada Health, Syndax Pharmaceuticals, Six Flags, and Immunic saw significant declines. Syndax dropped 15.7% after its Phase 2 trial for a lung disease drug failed, leading to halted developm...
Argo Graphene Solutions Corp. has granted incentive stock options to certain directors and consultants to purchase up to 1.2 million common shares at $1.25 each, exercisable until October 9, 2029. These options vest immediately but are subject to a f...
